Q32 Bio Inc

AstraZeneca agreed to make a $2 billion strategic equity investment in Summit Therapeutics, sending the biopharmaceutical company's shares up 17.1% in premarket trading. The investment supports a collaboration combining Summit's flagship bispecific antibody, ivonescimab, with AstraZeneca's oncology pipeline, and AstraZeneca will acquire convertible preferred shares at a price equivalent to $18.36 per common share, a 10% premium to Summit's five-day volume-weighted average price. Fair Isaac tumbled 15% after the Federal Housing Finance Agency announced changes to mortgage pricing that will introduce competition to FICO's longstanding role in the mortgage credit-scoring market; FHFA Director Bill Pulte said Fannie Mae and Freddie Mac will consolidate their separate pricing matrices into a single unified grid that will incorporate VantageScore alongside the traditional FICO Classic score. CarMax rose 3.7% after reporting fiscal second-quarter earnings of $1.16 per share, beating analyst expectations of 68 cents, with revenue of $7.88 billion topping forecasts of about $7.06 billion. AAR Corp. surged 6.9% after announcing an agreement to acquire a 65% controlling interest in MRO Holdings at an implied enterprise value of $4 billion, alongside adjusted diluted EPS of $1.49 and revenue of $918 million that beat expectations. Netflix rose 1.4% after Deutsche Bank upgraded the streaming giant to Buy from Hold with a $95 price target, while AbCellera Biologics gained 2.1% on a JPMorgan Overweight initiation with a $17 price target and Q32 Bio rose 9.4% ahead of a key clinical data presentation at the European Academy of Dermatology and Venereology Congress in Vienna beginning Sept. 30.

Q32 Bio led biotech gainers Monday with shares soaring over 90% after its Phase 2 SIGNAL-AA trial of Bempikibart in severe alopecia areata showed 40% of patients in the modified intent-to-treat group achieved 20% or less scalp hair loss by Week 36. The company plans a registration-directed program in the first half of 2027 and also announced a $200 million public offering. Agenus jumped over 82% after entering an $85 million private placement to fund its planned Phase 3 ROBBIN1 trial of botensilimab and balstilimab in MSS colon cancer, with first patient dosing expected in early 2027. Actuate Therapeutics gained over 23% following last month's news that its drug Elraglusib will be evaluated in the BEACON2 pediatric neuroblastoma trial. Galectin Therapeutics rose over 13% after reaching an FDA agreement on the primary endpoint for its Phase 3 study of Belapectin in MASH cirrhosis. Amwell and Shoulder Innovations each gained over 11% on no specific news, with Amwell expecting second-quarter revenue of $48 million to $52 million and Shoulder Innovations raising its full-year revenue guidance to between $65 million and $68 million.

Shares of Q32 Bio soared after the company announced that its Phase 2a clinical trial of bempikibart for severe alopecia areata met its primary efficacy goal, showing a 35% average reduction in scalp hair loss severity with no serious treatment-related adverse events. Oppenheimer analyst Jay Olson doubled his price target to $40 and reiterated an outperform rating, while Wells Fargo analyst Derek Archila set a $66 target, citing improved odds of success. The stock pulled back about 7% in after-hours trading after Q32 Bio announced a $200 million stock offering to fund further trials.